↓ Skip to main content

Dove Medical Press

Article Metrics

Treatment options and outcomes for glioblastoma in the elderly patient.

Overview of attention for article published in Clinical Interventions in Aging, February 2014
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (55th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
82 Dimensions

Readers on

mendeley
125 Mendeley
Title
Treatment options and outcomes for glioblastoma in the elderly patient.
Published in
Clinical Interventions in Aging, February 2014
DOI 10.2147/cia.s44259
Pubmed ID
Authors

David Reardon, Nils Arvold, Nils D Arvold, David A Reardon

Abstract

Age remains the most powerful prognostic factor among glioblastoma (GBM) patients. Half of all patients with GBM are aged 65 years or older at the time of diagnosis, and the incidence rate of GBM in patients aged over 65 years is increasing rapidly. Median survival for elderly GBM patients is less than 6 months and reflects less favorable tumor biologic factors, receipt of less aggressive care, and comorbid disease. The standard of care for elderly GBM patients remains controversial. Based on limited data, extensive resection appears to be more beneficial than biopsy. For patients with favorable Karnofsky performance status (KPS), adjuvant radiotherapy (RT) has a demonstrated survival benefit with no observed decrement in quality of life. Concurrent and adjuvant temozolomide (TMZ) along with RT to 60 Gy have not been prospectively studied among patients aged over 70 years but should be considered for patients aged 65-70 years with excellent KPS. Based on the recent NOA-08 and Nordic randomized trials, testing for O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation should be performed routinely immediately after surgery to aid in adjuvant treatment decisions. Patients aged over 70 years with favorable KPS, or patients aged 60-70 years with borderline KPS, should be considered for monotherapy utilizing standard TMZ dosing for patients with MGMT-methylated tumors, and hypofractionated RT (34 Gy in ten fractions or 40 Gy in 15 fractions) for patients with MGMT-unmethylated tumors. The ongoing European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial will help clarify the role for concurrent TMZ with hypofractionated RT. For elderly patients with poor KPS, reasonable options include best supportive care, TMZ alone, hypofractionated RT alone, or whole brain RT for symptomatic patients needing to start treatment urgently. Given the balance between short survival and quality of life in this patient population, optimal management of elderly GBM patients must be made individually according to patient age, MGMT methylation status, performance score, and patient preferences.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Italy 1 <1%
Unknown 123 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 18 14%
Student > Bachelor 16 13%
Other 14 11%
Student > Master 14 11%
Researcher 14 11%
Other 30 24%
Unknown 19 15%
Readers by discipline Count As %
Medicine and Dentistry 63 50%
Agricultural and Biological Sciences 16 13%
Neuroscience 11 9%
Nursing and Health Professions 2 2%
Biochemistry, Genetics and Molecular Biology 2 2%
Other 8 6%
Unknown 23 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2017.
All research outputs
#8,414,719
of 15,289,877 outputs
Outputs from Clinical Interventions in Aging
#708
of 1,485 outputs
Outputs of similar age
#81,513
of 189,580 outputs
Outputs of similar age from Clinical Interventions in Aging
#17
of 52 outputs
Altmetric has tracked 15,289,877 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,485 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,580 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.